R&D revenue from two customers helped the business to offset weakness from the coronavirus pandemic.
News & Analysis: Codexis
The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.
CDXS earnings call for the period ending March 31, 2020.
The small-cap stock has been cut in half in the last year. Is a $650 million market cap too good to pass up?
The company expects a fourth straight year of stagnant product revenue -- and declining gross margin, to boot. Those are noteworthy red flags for investors.
The enzyme engineering company reported disappointing full-year 2019 operating results.
CDXS earnings call for the period ending December 31, 2019.
The stock has tumbled to start 2020. Can the next business update provide any relief to shareholders?
The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
This favorite of institutional shareholders remains off the radars of most retail investors.